TNFRSF17 and acute lymphoblastic leukemia: CD19-directed CAR-T are used in relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia [223], whereas B-cell maturation antigen (BCMA)-directed CAR-T are used in multiple myeloma [224].